Iovance Biotherapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. 

CEO
Frederick G. Vogt
CEOFrederick G. Vogt
Employees
975
Employees975
Headquarters
San Carlos, California
HeadquartersSan Carlos, California
Founded
2007
Founded2007
Employees
975
Employees975

IOVA Key Statistics

Market cap
1.58B
Market cap1.58B
Price-Earnings ratio
-3.47
Price-Earnings ratio-3.47
Dividend yield
Dividend yield
Average volume
23.14M
Average volume23.14M
High today
$3.94
High today$3.94
Low today
$3.76
Low today$3.76
Open price
$3.80
Open price$3.80
Volume
3.60M
Volume3.60M
52 Week high
$5.63
52 Week high$5.63
52 Week low
$1.64
52 Week low$1.64

Stock Snapshot

Iovance Biotherapeutics(IOVA) stock is priced at $3.84, giving the company a market capitalization of 1.58B. It carries a P/E multiple of -3.47.

On 2026-03-18, Iovance Biotherapeutics(IOVA) stock traded between a low of $3.76 and a high of $3.94. Shares are currently priced at $3.84, which is +2.2% above the low and -2.5% below the high.

The Iovance Biotherapeutics(IOVA)'s current trading volume is 3.6M, compared to an average daily volume of 23.14M.

During the past year, Iovance Biotherapeutics(IOVA) stock moved between $1.64 at its lowest and $5.63 at its peak.

During the past year, Iovance Biotherapeutics(IOVA) stock moved between $1.64 at its lowest and $5.63 at its peak.

IOVA News

Simply Wall St 22h
Iovance Biotherapeutics Is Down 25.3% After Strong Early TIL Sarcoma Data Spurs Registrational Trial - What's Changed

In February 2026, Iovance Biotherapeutics reported early pilot data showing its lifileucel TIL therapy produced a 50% objective response rate in six evaluable p...

Iovance Biotherapeutics Is Down 25.3% After Strong Early TIL Sarcoma Data Spurs Registrational Trial - What's Changed

Analyst ratings

73%

of 11 ratings
Buy
72.7%
Hold
27.3%
Sell
0%

People also own

Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.